Societies, associations and institutes develop clinical guidelines for the treatment and management of Psoriasis at local, national, and international levels. The selections of guidelines below will aid healthcare professionals in the diagnosis, treatment, and management of their patients.


Topical treatment guidelines

Guidelines for the management of psoriasis with topical therapies were developed by the American Academy of Dermatology (AAD) in 2009 (Menter et al., 2009). These guidelines highlight that the majority of patients with psoriasis have limited disease (<5% body surface area [BSA] involvement) and can be safely and effectively treated with topical agents tailored to meet individual patients’ needs (Menter et al., 2009). Updates to these guidelines are expected to be published by the AAD in collaboration with the National Psoriasis Foundation (NPF) in the second quarter of 2020. All AAD guidelines can be accessed below.

Joint AAD-NPF guidelines on biologic and non-biologic treatment

All AAD guidelines can be accessed below. Joint AAD-NPF guidelines highlight that anti-TNF biosimilars approved by the FDA should be considered as interchangeable with the reference brand and that biologics may lose efficacy in patients who initially respond well to treatment (Menter et al., 2019).

Joint AAD-NPF guidelines of care for the management of psoriasis with non-biologics are expected in the first quarter of 2020.

Psoriasis and comorbidity guidelines

To help ensure physicians include prompt diagnosis of concomitant disease and prevent and treat any comorbidity, the EADV developed a precise, easy-to-use tool for systematising the diagnosis of comorbidity in patients with psoriasis and facilitate decision making regarding referral and treatment of patients diagnosed with an associated disease.

Login/ Register Maximise Minimise